IHL42X + Acetazolamide 250 MG + Dronabinol 2.5 MG
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Sleep Apnea
Conditions
Obstructive Sleep Apnea
Trial Timeline
Sep 8, 2023 → Jul 31, 2024
NCT ID
NCT05857384About IHL42X + Acetazolamide 250 MG + Dronabinol 2.5 MG
IHL42X + Acetazolamide 250 MG + Dronabinol 2.5 MG is a phase 1 stage product being developed by Incannex Healthcare for Obstructive Sleep Apnea. The current trial status is completed. This product is registered under clinical trial identifier NCT05857384. Target conditions include Obstructive Sleep Apnea.
What happened to similar drugs?
20 of 20 similar drugs in Obstructive Sleep Apnea were approved
Approved (20) Terminated (2) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05857384 | Phase 1 | Completed |
Competing Products
20 competing products in Obstructive Sleep Apnea